COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health, Inc. announces initiation of clinical trial for crofelemer in rare diseases SBS-IF and MVID. First proof-of-concept results expected in H1 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Jaguar Health and Napo Pharmaceuticals extend collaboration with Streeterville related to development of NP-300 drug product candidate for cholera patients, aiming for Tropical Disease Priority Review Voucher from FDA -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. founder Lisa Conte to present virtually at Emerging Growth Conference on Feb 18, 2025. Company focuses on sustainable pharmaceuticals derived from rainforest plants for gastrointestinal distress
